Navigation Links
Neptune Technologies & Bioressources Inc. reports first quarter results

LAVAL, QC, Oct. 10 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced financial results for the fiscal 2009 first quarter ended August 31, 2008.

Total revenue for the three-month period ended August 31, 2008 was $2,366,000 compared to $2,085,000 for the first quarter ended August 31, 2007, representing an increase of 13.5%.

The Company substantially decreased its net loss by 43% to $599,000, or $0.016 per share, for the three-month period ended August 31, 2008, compared to a net loss of $1,051,000, or $0.029 per share, for the three-month period ended August 31, 2007. Excluding non-monetary items, stock option based compensation and amortization, Neptune would have generated a profit of $344,000 for the three-month period ended August 31, 2008.

Neptune continues to generate positive cash flow during the three months ended August 31, 2008 and the Company's cash, cash equivalents and short-term deposits amounted to $2,151,000 on August 31, 2008. In addition, the Company announced recently that it successfully completed a $2,750,000 debenture financing to be used to support the achievement of several value-creating development and commercialization milestones of Acasti Pharma, its pharmaceutical subsidiary.

About Neptune

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is carrying out clinical research to show the therapeutic benefits in various medical indications. The Company patents and protects its innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnership with worldwide leaders in the nutraceutical industries. Neptune signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):